Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Change in Intangibles (2016 - 2025)

Historic Change in Intangibles for Lexaria Bioscience (LEXX) over the last 10 years, with Q4 2025 value amounting to $5099.0.

  • Lexaria Bioscience's Change in Intangibles fell 6125.09% to $5099.0 in Q4 2025 from the same period last year, while for Nov 2025 it was $59441.0, marking a year-over-year decrease of 4993.35%. This contributed to the annual value of $75106.0 for FY2025, which is 4841.3% down from last year.
  • Latest data reveals that Lexaria Bioscience reported Change in Intangibles of $5099.0 as of Q4 2025, which was down 6125.09% from $14610.0 recorded in Q3 2025.
  • In the past 5 years, Lexaria Bioscience's Change in Intangibles registered a high of $70727.0 during Q2 2021, and its lowest value of $2991.0 during Q1 2021.
  • Over the past 5 years, Lexaria Bioscience's median Change in Intangibles value was $26573.0 (recorded in 2024), while the average stood at $30558.1.
  • In the last 5 years, Lexaria Bioscience's Change in Intangibles soared by 29900000.0% in 2021 and then plummeted by 6712.39% in 2024.
  • Over the past 5 years, Lexaria Bioscience's Change in Intangibles (Quarter) stood at $15840.0 in 2021, then dropped by 9.46% to $14342.0 in 2022, then soared by 179.08% to $40026.0 in 2023, then plummeted by 67.12% to $13159.0 in 2024, then tumbled by 61.25% to $5099.0 in 2025.
  • Its Change in Intangibles stands at $5099.0 for Q4 2025, versus $14610.0 for Q3 2025 and $13159.0 for Q4 2024.